Compare QSR & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QSR | RVMD |
|---|---|---|
| Founded | 1954 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2B | 30.1B |
| IPO Year | 2014 | 2020 |
| Metric | QSR | RVMD |
|---|---|---|
| Price | $78.20 | $208.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 19 |
| Target Price | $81.35 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 2.1M | 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $9,434,000,000.00 | N/A |
| Revenue This Year | $5.34 | N/A |
| Revenue Next Year | $1.88 | $533.02 |
| P/E Ratio | $32.26 | ★ N/A |
| Revenue Growth | ★ 12.23 | N/A |
| 52 Week Low | $61.33 | $37.88 |
| 52 Week High | $81.96 | $224.31 |
| Indicator | QSR | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 62.44 |
| Support Level | $71.21 | $177.04 |
| Resistance Level | $79.53 | $220.34 |
| Average True Range (ATR) | 1.55 | 7.88 |
| MACD | 0.17 | 0.07 |
| Stochastic Oscillator | 62.49 | 63.85 |
Restaurant Brands generates about $47 billion in system sales across more than 33,000 restaurants in over 120 markets, making it one of the largest restaurant companies globally. Its banners include Burger King (7,025 stores), Tim Hortons (4,586), Popeyes (3,578), and Firehouse Subs (1,449), concentrated in the US and Canada, with these brands also comprising 16,403 franchised international locations as of year-end 2025. The firm primarily earns revenue from franchise and property fees, supply chain sales within the Tim Hortons segment, company-operated restaurants, and advertising royalties.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.